The smarter E AWARD 2025: Energy Transition Pioneers Shortlisted
The winners of The smarter E AWARD 2025 will be honored on 6 May at the International Congress Center Messe München. The finalists are the following.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320037540/en/
The finalists for The smarter E AWARD 2025 have been announced in the five categories. ©Solar Promotion GmbH
Finalists in the Photovoltaics category
- 7Secondsolar (South Africa) with its AUTOPV planning software solution
- Aevy (Norway) with its Aevy asset management platform
- Aiko Energy (China) with its ABC INFINITE PV module
- Anhui Huasun Energy (China) with its Kunlun Series Ultra-high Bifaciality HJT solar module
- LONGi Solar Technology (China) with its Hi-MO X10 module
- MBJ Solutions (Germany) with its MBJ Sunlike Lab solar simulator
- Seaward Electronic (UK) with its PV:1525-IV testing device
- Sungrow Power Supply (China) with its SG350HX-20 string inverter
- Sunmaxx PVT (Germany) with its Sunmaxx PX-1 combination module
- Weidmüller Interface (Germany) with its PV Inline lightning and overvoltage protection
Finalists in the Energy Storage category
- CMBlu Energy (Germany) with its Organic SolidFlow Battery storage system
- EcoFlow (China) with its PowerOcean DC Fit residential storage system
- EVE Energy (China) with its Mr. Big battery cell
- Huawei Technologies (China) with its ESS LUNA2000-215-2S10 storage system
- Hydrostor (Canada) with its A-Compressed Air Energy Storage (A-CAES) system
- p&e power&energy (Germany) with its Scalable Cell Level Power Electronics Platform inverter system
- SAMSUNG SDI (South Korea) with its U8A1 UPS solution
- SOL Research (Germany) with its Powerstation 2.500
- Sungrow Power Supply (China) with its PowerTitan 2.0 large-scale storage system
- Xiamen Hithium Energy Storage Technology (China) with its Power 6.25 MWh 4h BESS battery container
Finalists in the E-Mobility category
- Cable-Sherpa (Austria) with its Cable-Sherpa cable management
- DEHN (Germany) with its DEHNguard M DC ACI 1250 FM power protection switch
- Etecnic (Spain) with its EVcharge Software-as-a-Service (SaaS) platform
- Friedrich (Germany) with its URBANROOF parking lot canopy
- GoodWe (China) with its Vela Series Residential Solar Carport
- Hive Power (Switzerland) with its Hive Power FLEXO Smart Charge SaaS solution
- SAMSUNG SDI (South Korea) with its No Thermal Propagation Technology battery concept
- Schaltbau (Germany) with its C330 high-power DC contactor
- Shenzhen Kehua Hengsheng Technology (China) with its EV3102-040K-HR-UC SiC charging module
- OPES Solar Mobility (Germany) with its O.Motion matrix solar module series
- Schaltbau (Deutschland) mit dem Hochleistungs-DC-Schütz C330
- Shenzhen Kehua Hengsheng Technology (China) mit dem SiC-Lademodul EV3102-040K-HR-UC
- OPES Solar Mobility mit der Matrix-Solarmodul-Serie O.Motion
Finalists in the Smart Integrated Energy category
- FENECON (Germany) with its FEMS FENECON energy management system
- meteocontrol (Germany) with its mc Assetpilot
- fleXality (Germany) with its AI-based fEnOMS software solution
- Sungrow Power Supply (China) with its Stem Cell Grid Technology grid-forming inverter technology
- Toscano (Spain) with its COMBI-PRO-MAX switching solution
- Utiligize (Denmark) with its integrated Forecast & Investment platform
- Zählerfreunde (Germany) with its white label energy management SaaS solution for utilities
Finalists in the Outstanding Projects category
- Beijing HyperStrong Technology (China) with its Beijing Siyuanqiao Integrated Charging Plus Storage Station Project
- Beijing HyperStrongTechnology (China) with its 250 MW/1,000 MWh energy storage project in Santanghu
- CyberGrid (Austria) with its Theiß Hybrid Storage System
- Electricity Authority of Cyprus (Cyprus) with its installation of PV systems in 405 public schools
- GIZ Indonesia (Indonesia) with its off-grid Solar Ice Maker project for fishing communities
- Karlsruhe Institute of Technology – KIT (Germany) with its BiFlow hybrid storage system project
- LONGi Solar Technology (China) with its 3000 Nm³/h Electrolyzer in Hydrogen-Rich Blast Furnace Smelting project
- Phaesun (Germany) with its BeCool: Clean Cooling for Markets in Kenya project
- Sungrow Hydrogen (China) with its Low Carbon Institute Green Hydrogen Demonstration Project
- Xiamen Ampace Technology (China) with its energy storage project integrated into a high-voltage transformer station in Chile
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320037540/en/
Contacts
Solar Promotion GmbH | Peggy Härter-Zilay | Tel.: +49 7231 58598-240
haerter-zilay@solarpromotion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category28.3.2025 15:22:00 EET | Press release
Altasciences, a nine-time CRO Leadership Award winner, is proud to announce they have been awarded a 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327305519/en/ Altasciences receives a 2025 CDMO Leadership Award in the Small Molecule Dosage Form (North America) category. Altasciences’ CDMO site supports drug development with formulation, manufacturing, and analytical testing—from discovery to commercialization. Their FDA-inspected facility features Grade C cleanrooms, R&D and analytical labs, ICH stability chambers, and a cGMP warehouse. "This recognition reflects our CDMO team’s unwavering dedication and expertise, as well as our unrelenting commitment to advancing drug development in collaboration with leading pharmaceutical and biotech innovators,” says Marie-Hélène Raigneau, Co-Chief Operating Officer at Altasciences. “We are gratefu
SES and SpeQtral Sign MoU to Advance Global Quantum-Secure Communications28.3.2025 14:49:00 EET | Press release
SES and SpeQtral signed a Memorandum of Understanding (MoU) to develop an interoperable Optical Ground Station (OGS) to establish long-distance satellite-based Quantum Key Distribution (QKD) between Asia and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328851677/en/ SES's CEO Adel Al-Saleh and SpeQtral's CEO Chune Yang Lum sign a Memorandum of Understanding to develop an interoperable Optical Ground Station to establish long-distance satellite-based Quantum Key Distribution between Asia and Europe. Under the agreement, the development of an interoperable OGS will enable SES and SpeQtral to connect both companies’ current and future QKD satellite missions, resulting in easier access to, and diversity in the supply of long-distance QKD to end users in Asia, Europe and other future compatible ground stations worldwide. The integration of this proposed OGS with Singapore’s fibre-QKD network will help future customer
SBC Medical Group Holdings Inc. Announces Fourth Quarter and Full Year 2024 Financial Results28.3.2025 13:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical” or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for -the three months ended December 31, 2024 and full year 2024. Fourth Quarter 2024 Highlights Total revenues were $44 million, representing a 29% year-over-year decrease. Gross profit was $34 million, representing a 22% year-over-year decrease. Income from operations was $5 million, representing an 80% year-over-year decrease. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $21 million, representing a 22% year-over-year decrease. EBITDA margin1was 47% for the fourth quarter of 2024, compared to 43% for the fourth quarter of 2023. Net income attributable to SBC Medical Group was $7 million, representing a 54% year-over-year decrease. Earnings per share, which is defined as net inc
SINOVAC Announces New Board Member and Chairman of the Audit Committee28.3.2025 13:00:00 EET | Press release
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under Nasdaq Rule 5605, Mr. Borho has also been elected as the Chair of the Audit Committee of the Board. Mr. Borho is a founder and Managing Partner of OrbiMed and has over 30 years of experience investing in the healthcare sector. OrbiMed is a leading healthcare investment firm with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds and royalty/credit funds. OrbiMed funds have been shareholders of SINOVAC since 2013 and currently hold over 2.7 million shares. Following this appo
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta ® (pertuzumab) Biosimilar Candidate HLX1128.3.2025 12:00:00 EET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for HLX11, an investigational biosimilar of Perjeta® (pertuzumab). Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer, and adjuvant treatment for certain HER2-positive early breast cancer, among other indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328881021/en/ The submission was based on a multicenter, randomized, double-blind, parallel-controlled phase 3 clinical study (NCT05346224) aimed to compare the efficacy and safety of HLX11 with reference Perjeta® (pertuzumab) as a neoadjuvant therapy in patients with HER2-positive, HR-negative early-stage, o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom